Trends in Dupuytren Treatment in the United States
Fig. 4.1 Number of DC diagnoses by quarter Since the approval of CCH in Q1 2010, the use of CCH has steadily increased from 5 % of all DC procedures…
Is Recurrence After Treatment Predictable? Risk Factors in Dupuytren Disease
© Springer International Publishing Switzerland 2017Paul M. N. Werker, Joseph Dias, Charles Eaton, Bert Reichert and Wolfgang Wach (eds.)Dupuytren Disease and Related Diseases – The Cutting Edge10.1007/978-3-319-32199-8_39 39. Is Recurrence After Treatment Predictable? Risk Factors in Dupuytren Disease…
Treatment of Dupuytren Disease: Where Are We Now?
(Cline 1777) It does not appear that Dupuytren met with any mischief when he did the operation in this way……. . I think it would be altogether impossible to escape suppuration…
Use of Digital Photography and Mobile Device Application to Assess Finger Deformity in Dupuytren Disease
Fig. 30.1 Mobile device application measurements of Dupuytren contracture. With the aid of the mobile device application, lines are superimposed of the mid-axes of the affected fingers as judged by…
The Intra- and Interobserver Agreement on Diagnosis of Dupuytren Disease, Measurements of Severity of Contracture, and Disease Extent
Fig. 28.1 Use of the tumorimeter. (a) The nodule is encircled, (b) the loop is placed over the nodule, whereafter the surface area can be read off 28.2.3 Procedure All…
Controversy: Comparison of the Literature on PNF and CCH as Minimally Invasive Treatment Options for Dupuytren Disease
Author Lermusiaux et al. (2001) Foucher et al. (2003) Van Rijssen et al. (2006) Pess et al. (2012) Hurst et al. (2009) PNF PNF PNF PNF CCH SAE Tendon…
Collagenase: What We May Never Know (A Discussion)
Fig. 19.1 Risk matrix 19.4.5 Recurrence as an Outcome Measure This poses a particular problem. There is no accepted definition of recurrence. A recurrence may hold different value after different…
Efficacy of Using Local Anesthesia Before Collagenase Injection in Reducing Overall Pain Experience in Patients Treated for Dupuytren Contracture: A Quasi-Randomized Study
Fig. 15.1 Experienced pain during injection and interval. Mean visual analog scale (VAS) scores for pain experienced during the first injection (buffered mepivacaine in the local anesthesia [LA] group; collagenase…
Collagenase Injection: Journey from Bench to Current Advanced Clinical Use
Injectable clostridial collagenase is a promising treatment for patients with Dupuytren contracture. Dose-ranging, phase 2 clinical trials identified an optimal collagenase dose of 10,000 units (0.58 mg), balancing excellent clinical…
Tumour Necrosis Factor as a Therapeutic Target in Dupuytren Disease
Fig. 8.1 Dupuytren myofibroblasts. (a) Immunofluorescence staining of Dupuytren myofibroblasts in a 3D collagen matrix. Cell matrix junctions stained for integrin β1 (red), F actin (phalloidin) (green) and nuclei stained…
